IMR Press / EJGO / Volume 24 / Issue 1 / pii/2003113

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer

Show Less
1 Department of Obstetrics and Gynecology, Alcalá de Henares University, Madrid, Spain
2 Department of Biochemisty, “Príncipe de Asturias” Hospital, Alcalá de Henares University, Madrid, Spain
3 Department of Especialidades Médicas, Alcalá de Henares University, Madrid, Spain
Eur. J. Gynaecol. Oncol. 2003, 24(1), 60–62;
Published: 10 February 2003
Abstract

Purpose of investigation: The clinical use of tumor markers during breast cancer follow-up is still surrounded by controversy. The objective of this study consisted of determining the contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer patients as applied to clinical practice Methods: Three hundred and eighteen cases of women with breast cancer were analyzed retrospectively as far as the sensitivity, the specificity and the positive and negative predictable values of the CA 15.3 and CEA markers. Results: Of the 318 patients, 59 suffered a relapse during the study. After evaluation of both markers the sensitivity was 56.8% (CA 15.3: 47.4%), the specificity 85.3% (CA 15.3: 88.4%), the positive predictable value was 46.4% (CA 15.3: 48.2%) and the negative predictable value was 89.41% (CA 15.3: 88%). Conclusions: The low sensitivity of studied tumor markers proved of limited use on a clinical scale.

Keywords
Breast cancer
Tumor markers
CA 15.3
CEA
Follow-up
Share
Back to top